Mekhail Extension of the Motzer Score

Adds prior radiotherapy and metastatic site burden to the Motzer model to refine prognostic risk stratification in metastatic RCC.

LDH > 1.5x upper limit of normal (normal: 140 U/L)
No0Yes+1
Hb < lower limit of normal (normal: < 12 g/dL (120 g/L)
No0Yes+1
Corrected serum calcium > 10 mg/dL (2.5 mmol/L)
No0Yes+1
Time from initial diagnosis to systemic treatment < 1 year
No0Yes+1
Prior treatment with radiation
No0Yes+1
≥ 2 sites of metastasis
No0Yes+1

Indications for Use

Used for previously untreated metastatic RCC to refine MSKCC risk groups by adding prior radiotherapy and number of metastatic sites (0–1 vs 2–3). It improves prognostic discrimination and stratifies patients into favorable (0–1 factors), intermediate (2), and poor (>2) risk to guide counseling and clinical‑trial selection (median OS 26.0, 14.4, 7.3 months respectively; 353‑patient cohort) 1 [Level II evidence].

Insights & Cautions

Incorporates metastatic-site burden (≥2 sites) and prior radiotherapy to refine risk grouping, improving discrimination over the original Motzer model (median OS 26 vs 14.4 vs 7.3 months across favorable/intermediate/poor groups) 1 [Level II evidence].
Cautions: derived in the cytokine era, not validated for modern VEGF‑TKI or ICI therapy; risk inflation possible when metastatic distribution is heterogeneous; should not supersede IMDC for treatment selection.